Brainsway
Advanced Technology Solutions for Brain Disorders
StartupBrainsway is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2003. Advanced Technology Solutions for Brain Disorders. The company has raised a total of $79.95M across 6 funding rounds, currently at the Public stage. Brainsway was founded by Avner Hagai, Yiftach Roth, David Zacut, Abraham Zangen. Key investors include Valor Equity Partners , IBI Investment House, Noked Capital, among 6 total investors. The company has 51-200 employees.
With $79.95M in total funding, Brainsway is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Released. The company holds 1 patent.
- StagePublic
- ProductReleased
- ModelB2B
- Employees51-200
- HQJerusalem
- DistrictJerusalem District
- Last Round$20M
- Valor Equity Partners Lead
- IBI Investment House
- Noked Capital
6 investors total
Avner HagaiCo-founder
Yiftach RothCo-founder
David ZacutCo-founder 
Abraham ZangenCo-founder & Scientific Consultant
202 articles covered by sources including finance.yahoo.com,
www.globenewswire.com,
www.biospace.com,
www.globes.co.il,
www.calcalistech.com.
What does Brainsway do?
BrainsWay develops advanced noninvasive neurostimulation treatments for mental health disorders. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology aims to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction. The company's flagship technology is based on deep transcranial magnetic stimulation, aimed at helping smokers quit (FDA cleared since August 2020). BrainsWay's technology is based on patents filed by the US National Institutes of Health (NIH) and by the company. The company holds an exclusive license from the NIH for the patent and its technology. BrainsWay is FDA cleared for treating adult patients with major depressive disorder who have failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. BrainsWay is also approved in Canada for the treatment of major depressive disorder. It is also FDA cleared as an intended adjunct treatment for adult patients with obsessive-compulsive disorder. Furthermore, BrainsWay holds CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions including post-traumatic stress disorder and Alzheimer's disease. BrainsWay collaborates with scientists and academic research institutions worldwide in clinical trials covering various neuropsychiatric and neuroscience applications.
How much funding has Brainsway raised?
Brainsway has raised $79.95M in total funding across 6 rounds. The company is currently at the Public stage. Key investors include Valor Equity Partners , IBI Investment House, Noked Capital.
Who founded Brainsway?
Brainsway was founded in 2003 by Avner Hagai (Co-founder), Yiftach Roth (Co-founder), David Zacut (Co-founder ), Abraham Zangen (Co-founder & Scientific Consultant).
What sector is Brainsway in?
Brainsway operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients.
Where is Brainsway located?
Brainsway is based in Hartom Street 19, Jerusalem, Israel, Jerusalem District. The company also has offices abroad.